Dihexa vs Pinealon.

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; also referenced as PNB-0408) is a small, orally active peptidomimetic derived from angiotensin IV (Ang IV), a C-terminal fragment of the renin-angiotensin system. It was designed at Washington State University by chemically modifying Ang IV to increase lipophilicity and metabolic stability, yielding a brain-penetrant molecule investigated as a procognitive / antidementia research agent. It is a research chemical, not a drug; it has never been an approved medicine.

Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to the class of "peptide bioregulators" developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, who designed short peptides intended to mirror regulatory sequences associated with the pineal gland. It is a research chemical, not an approved drug.

Dihexa was developed from Ang IV, whose procognitive effects were originally studied at the AT4/IRAP site, but its proposed primary mechanism is potentiation of hepatocyte growth factor (HGF) signaling through its receptor tyrosine kinase c-Met, which drives dendritic spine formation (spinogenesis) and synaptogenesis in hippocampal neurons. Activating HGF/c-Met is thought to remodel synaptic connectivity rather than act as a classical neurotransmitter. Important caveat: the central biochemical evidence that dihexa works by binding HGF and augmenting HGF/c-Met activation came from a paper that has since been retracted for data fabrication, so the molecular mechanism should be treated as unproven. The downstream behavioral phenotype (improved spatial learning in rodents) was reported in separate, non-retracted work.

The proposed mechanism, advanced primarily by the Khavinson group, is that short peptides like EDR penetrate cell and nuclear membranes and interact directly with DNA and chromatin to act as epigenetic modulators of gene expression and protein synthesis. In cell and biophysical studies the EDR peptide has been reported to bind deoxyribooligonucleotides/DNA and to enter the nucleus of HeLa cells, and proposed downstream effects include reduced reactive oxygen species, modulation of MAPK/ERK signaling, lowered pro-apoptotic markers (caspase-3, p53), increased antioxidant enzymes (SOD2, GPX1), and stimulation of serotonin-related (tryptophan hydroxylase) expression in cortical neurons. These are mechanistic hypotheses derived largely from in vitro and computational/biophysical work rather than from established receptor pharmacology.

There is NO human data on dihexa: no completed clinical trials, no published human pharmacokinetics or safety. The non-retracted foundational study (McCoy et al., J Pharmacol Exp Ther 2013, PMID 23055539) reported that orally administered dihexa reversed scopolamine-induced learning deficits and improved Morris water maze performance in aged (24-month) rats, and induced spinogenesis in cultured hippocampal neurons at picomolar concentrations. Later angiotensin-IV-analog work continued in disease models (e.g., a 2024 study of an Ang IV analog in a 3-nitropropionic-acid Huntington's-like rat model, PMID 38489193). Crucially, the most-cited mechanistic paper tying dihexa's cognitive effects to HGF/c-Met (Benoist et al., J Pharmacol Exp Ther 2014, PMID 25187433) was RETRACTED in 2025 (retraction notice PMID 40312093) after a Washington State University investigation found falsified/fabricated figure data; the widely repeated "thousands of times more potent than BDNF" claim derives from this now-discredited line of work and should not be cited as established fact. The honest summary: rodent behavioral evidence exists, but the headline mechanistic and potency claims rest partly on retracted literature, and human efficacy is entirely unestablished.

There are no completed human efficacy trials of pinealon; the evidence base is preclinical (in vitro cell culture, biophysical, and rodent) and clusters heavily around a single research lineage. Reported findings include increased neuronal cell viability and suppression of free radicals in culture (Khavinson, Rejuvenation Research 2011), nuclear penetration and DNA binding of fluorescently labeled short peptides (Fedoreyeva, Biochemistry Moscow 2011), stimulation of serotonin expression in brain cortex cells (Khavinson, Bull Exp Biol Med 2014), and antioxidant/neuroprotective effects in aged-rat hypoxia and carotid-occlusion models (Mendzheritsky, Adv Gerontol 2011, 2014). A 2020 Molecules review by the developers frames EDR as a candidate neuroprotective agent for early Alzheimer's disease, but it is a hypothesis-generating review of the group's own animal and in vitro data, not clinical proof. Independent, non-affiliated replication is essentially absent, so reported effects should be treated as preliminary.

No human safety data exist; there is no published clinical adverse-event profile, and dihexa is sold only as a research chemical of variable purity. The principal theoretical concern follows directly from its proposed mechanism: c-Met is a validated oncology target because aberrant HGF/c-Met signaling promotes tumor proliferation, invasion, angiogenesis, and metastasis, so a chronic c-Met potentiator raises an unresolved oncogenic-risk question that no human study has addressed. Its reported long circulating half-life and high lipophilicity also mean tissue accumulation and off-target effects are poorly characterized. Because foundational mechanistic data were retracted for fabrication, even the basic biology underlying any risk assessment is uncertain.

Documented safety data in humans are effectively nonexistent; there are no published controlled human safety or pharmacokinetic trials, and no established toxicology dossier in the peer-reviewed literature. Materials sold as "pinealon" are research chemicals not manufactured to pharmaceutical GMP standards, so identity, purity, sterility, and endotoxin content are unverified and vary by vendor. Long-term effects, immunogenicity, and any consequences of the proposed DNA-interacting mechanism are unstudied in humans. Because the compound is unapproved and unregulated for human use, its risk profile is genuinely unknown rather than established as safe.

Dihexa is investigational/research-use-only: it is not approved by the FDA or any major regulator for any indication, has no DailyMed monograph, and has not completed human clinical trials. It is not a dietary supplement and is widely sold only as a "research chemical." It is not a WADA-listed named substance, though non-approved experimental compounds are broadly disallowed in sport.

Pinealon is not approved by the FDA or, to public knowledge, any major regulatory authority; it has no ATC code and no standard pharmaceutical identifiers (DrugBank/KEGG/UNII), and is sold only as a research-use-only chemical. It is not a recognized therapeutic and is not WADA-listed as a named substance, though related growth/peptide categories may fall under broader anti-doping provisions.